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Abstract
Background: Patent medicine vendors (PMV) provide antimalarial treatment and care throughout Sub-Saharan Africa, and
can play an important role in the fight against malaria. Their close-to-client infrastructure could enable lifesaving
artemisinin-based combination therapy (ACT) to reach patients in time. However, systematic assessments of drug sellers’
performance quality are crucial if their role is to be managed within the health system. Lot quality assurance sampling
(LQAS) could be an efficient method to monitor and evaluate PMV practice, but has so far never been used for this purpose.
Methods: In support of the Nigeria Malaria Booster Program we assessed PMV practices in three Senatorial Districts (SDs) of
Jigawa, Nigeria. A two-stage LQAS assessed whether at least 80% of PMV stores in SDs used national treatment guidelines.
Acceptable sampling errors were set in consultation with government officials (alpha and beta ,0.10). The hypergeometric
formula determined sample sizes and cut-off values for SDs. A structured assessment tool identified high and low
performing SDs for quality of care indicators.
Findings: Drug vendors performed poorly in all SDs of Jigawa for all indicators. For example, all SDs failed for stocking and
selling first-line antimalarials. PMV sold no longer recommended antimalarials, such as Chloroquine, Sulfadoxine-
Pyrimethamine and oral Artesunate monotherapy. Most PMV were ignorant of and lacked training about new treatment
guidelines that had endorsed ACTs as first-line treatment for uncomplicated malaria.
Conclusion: There is urgent need to regularly monitor and improve the availability and quality of malaria treatment
provided by medicine sellers in Nigeria; the irrational use of antimalarials in the ACT era revealed in this study bears a high
risk of economic loss, death and development of drug resistance. LQAS has been shown to be a suitable method for
monitoring malaria-related indicators among PMV, and should be applied in Nigeria and elsewhere to improve service
delivery.
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Introduction
Patent medicine vendors (PMVs) provide antimalarial treatment
and care throughout Sub-Saharan Africa. They potentially play a
critical role in the fight against malaria. However, systematic
assessment of their performance quality is crucial for their
management within the health system. Such an assessment can
complement quality assurance through health facility assessments
(HFAs) [1,2,3,4,5].
Malaria remains a leading cause of morbidity and mortality in
Africa with an estimated 176 million cases and 709,000 deaths
recorded in 2009. About 25% occur in Nigeria [6]. Although early
diagnosis and prompt treatment is a principal strategy for global
malaria control [6] only 26% of malaria cases in ,5-year-old
children in Nigeria were treated on the same or next day with
‘‘any antimalarial’’ and 3% with artemisinin-based combination
therapy (ACT) [7]. In 2001 the World Health Organization
(WHO) recommended ACT as the first-line treatment for
uncomplicated malaria as a response to increasing Chloroquine
(CQ) and Sulfadoxine-Pyrimethamine (SP) drug resistance [8].
ACT has meanwhile been officially adopted by most African
countries including Nigeria (since 2005), but uptake remains slow
[6].
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Many people do not attend health facilities and choose self-
medication through the often unregulated private retail market
[7,9,10]. The WHO has encouraged participation of formal and
informal private providers, such as PMVs, to implement
government strategies for malaria control [3]. PMVs do not have
formal pharmacy training but ‘‘sell orthodox pharmaceutical
products on a retail basis for profit’’ [11]. Medicine vendors are
ubiquitous in Africa and can be found even in remote villages and
shantytowns [11,12]. Because they are culturally and economically
accessible, they are often the first choice for malaria treatment,
especially in rural areas [2,13,14]. In rural Nigeria about 60% of
mothers prefer to consult PMVs rather than other providers for
treatment of childhood malaria [2]. Since PMVs form an
established network, they provide an entry point for government
interventions to distribute ACTs [15,16]. ACTs have been
declassified from prescription only to an over-the counter (OTC)
medicine since 2005, thus allowing its dissemination by PMVS,
whose patent and proprietary medicine vendor license only
authorizes the selling of OCT drugs [17]. However, inadequate
knowledge among PMVs and other structural or behavioral
factors could lead to misdiagnosis, over- and under-treatment with
drugs, and delayed referrals with increased risk of disease
progression, toxicity and development of drug resistance
[5,12,13,18]. Drug resistance is a particular concern following
introduction of ACTs because continued use of artemisinin-
derivates as oral monotherapy could threaten the therapeutic life
of ACTs by fostering artemisinin resistance [19,20].
Malaria control strategies can take advantage of well-established
PMVs’ close-to-client provision of care only if they address their
technical failures and other factors that threaten the quality of
their services [11]. Such action requires not only baseline
assessments of PMVs’ performance to inform the design of
interventions, but also regular monitoring and evaluation (M&E)
of their services.
Several quantitative and qualitative studies have assessed the
quality of antimalarial treatment and care among medicine sellers
in Africa [1,5,9,12,13,21,22]. Nearly all were conducted prior to
the adoption of ACT as the first-line regimen. Despite the lack of
peer-reviewed publications about the availability and use of ACT
by PMVs in Nigeria, limited evidence suggests that PMVs’
knowledge of the 2005 policy change endorsing ACTs as the new
first-line antimalarial is low and ACT uptake is slow [4,23].
To improve service delivery, research is needed to assess the
adherence to international and national treatment guidelines by all
health system stakeholders. Given the prevailing financial
constraints, this would only be feasible if an evidence based
method could be used that is not too costly and time-consuming.
Here, we propose Lot Quality Assurance Sampling (LQAS) as
such a method, because it uses a rapid, and inexpensive, but
nevertheless precise technique that requires only small sample sizes
to make meaningful statistical inferences. Lot Quality Assurance
Sampling (LQAS) has been used successfully to assess the quality
of care in other health arenas [24,25,26]. This paper uses LQAS
for the first time to assess the quality of local PMV services for
malaria treatment of the sick child. This work is one component of
a larger study by the Nigeria Malaria Control Program (NMCP)
[27] that assessed the quality of malaria and child health services.
Here, we report on the availability and quality of malaria drugs
and treatment advice among PMVs while demonstrating the use
of monitoring technique that can be used recurrently for
management purposes.
Methods
Sampling Design
States in Nigeria are divided into three Senatorial Districts
(SDs); each includes about one-third of all health facilities (HFs).
The study, implemented in Jigawa state, uses a two-stage LQAS
sampling-design. Firstly, a random sample of all public and formal
private primary and secondary HFs was selected in each SD.
Secondly, one PMV located closest to the sampled HF was
selected for study. If two or more PMV stores were of similar
distance from the HF we chose one of them randomly. As patients
leaving HFs with a diagnosis of malaria often have to purchase
antimalarials at PMVs due to their non-availability in HFs [28],
the greatest demand for antimalarials could be at the closest PMV.
Therefore, a sample of PMVs located close to HFs could measure
the quality of services in PMVs that experience the highest
demand for antimalarials. While a two-stage design has been used
in HFA-LQAS assessments [25,26,29], this PMV-LQAS design is
used for the first time (Table 1).
Using LQAS to Classify PMVs in Each SD
LQAS is a classification method originally developed for
industrial quality control during the 1920s [30]. The principle is
that a line supervisor examines a small random sample from a lot
of recently manufactured goods, e.g. light bulbs on an assembly
line. If the supervisor finds that the number of defective goods in
the small sample exceeds a predetermined number, the whole lot is
rejected. Otherwise it is accepted. The predetermined allowable
number of defective goods is called ‘‘decision rule’’. It is
determined statistically to ensure that there is a high probability
of correct classification, namely, that rejected lots contain a
relatively high proportion of defective goods, and that accepted
lots contain no or only a relatively low proportion of defective
goods. However, there always remains a small risk of misclassi-
fication, as reflected in the level of statistical error. The ‘‘alpha
error’’ is the probability of mistakenly rejecting a lot with no or
only very few defective goods, and the ‘‘beta error’’ is the
probability of mistakenly accepting a lot with too many defective
goods.
LQAS was adapted to health sciences in the mid-1980s [29] and
has meanwhile been widely used to monitor public health
applications [31]. In our application, the lots are defined as the
different SDs in Jigawa, including Central, North-East, and North-
West-SD that manage all the health facilities within their
geographical boundaries. The equivalent of a defective good
would be a health facility with an unacceptable level of service
quality. If after assessing a random sample ‘‘n’’ of all HFs in the
SD, a certain predetermined number of HFs fail to show
acceptable service quality, the SD is marked as an SD with
‘‘low’’ performance in need of special attention and resources for
quality improvement.
Health systems managers of the different SDs in Jigawa were
not only interested in the performance of HFs, but also in the
performance of PMV stores reported in this paper. Therefore, for
each SD a corresponding sample ‘‘n’’ of PMV stores was assessed.
While in industrial quality control it might be easy to assess
whether a good is defective, it is more complex to assess the service
quality and performance of PMV stores. We used the PMV-LQAS
tool adapted from previously validated tools [32] to assess different
aspects of PMV performance, including the quality of PMV
pediatric malaria treatment, the availability of antimalarials in
their stores, and their training and knowledge about malaria
prevention and treatment [33].
Medicine Vendors as Agents in Malaria Control
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The decision rule or cut-off ‘‘d’’ is the allowable number of
PMV stores out of the sample of ‘‘n’’ stores in an SD that have to
show acceptable performance for an SD to be classified in the
‘‘high’’ category with respect to a quality indicator. The cut-off
‘‘d’’ depends on the sample size (n), the level of misclassification
error (alpha and beta error) that managers are ready to accept,
and the thresholds that determine the minimum proportion ‘‘p’’ of
PMV stores that have to show acceptable service quality for an SD
to be classified as of ‘‘high’’ or ‘‘low’’ performance. Two thresholds
need to be determined: an upper threshold ‘‘pU’’ above which SD
performance will be classified as acceptable or ‘‘high’’, and a lower
threshold ‘‘pL’’ below which it will be classified as unacceptable or
‘‘low’’. Between these two thresholds is the area commonly
referred to as the ‘‘grey area’’ with SDs having intermediate
performance. As LQAS makes only binary decisions, SDs with
intermediate performance are also classified as high or low
depending on their proximity to either threshold. All of the
corresponding classification errors are depicted in an Operating
Characteristic Curve (Figure 1). LQAS’s strength is in identifying
SDs situated at the ends of the distribution of quality; it is therefore
sensitive to identifying SDs which are among the worst of the worst
with very low amounts of error and that can be targeted for
improvement. The National Malaria Control Program (NMCP)
set the upper threshold (pU) identifying acceptable performing SDs
as 80% of PMVs using the national guidelines. This threshold level
was decided by consensus during a stakeholder forum, in which
the directors and M&E officers of the NMCP, as well as
representatives of the World Health Organization and World
Bank participated. It is informed by coverage information
available in previous studies and is in line with the targets of the
Nigerian 5-year Strategic Plan 2006–2010 that stated that an 80%
coverage was both feasible and required to bring malaria under
control [17]. The lower threshold (pL), was set 30% lower (which is
typical), i.e. at 50%. The sample size (n) and decision rule (d) were
selected to minimize the two forms of misclassification errors, so
that the overall statistical error (a+b) was no more than 0.20.
For our PMV-LQAS design we used the hypergeometric
formula to calculate the sample size of PMVs due to the small
number of HFs in SDs [29]. This procedure generated a sample
size of n = 7 PMVs for North West-SD and North East-SD, and a
decision rule of d = 5, with an alpha error of 0.042, and
beta = 0.051 for pU= 80%, pL= 50%. In Central-SD the param-
eters were the same except that alpha#0.001, and beta = 0.083
(Table 1). These sample sizes can also be generated by entering all
the parameters into a web-based LQAS sampling plan calculator
using the hypergeometric distribution [34]. See [29] for more
detail about LQAS.
Data Collection and Ethics Statement
Data collectors were experienced Jigawa state health workers
trained during 16–19 March 2009. They collected data during 20–
26 March 2009 under the supervision of a state manager and an
author, after receiving written informed consent from all
participants. The study was approved by the Liverpool School of
Tropical Medicine Research Ethics Committee, and by the
Ministry of Health in Nigeria.
Analysis
LQAS classified the three Jigawa SDs as having acceptable
(pU= 80%) or unacceptable (pL = 50%) performance using a
statistically determined decision rule (d = 5). We then aggregated
the resulting data across the three SDs to calculate a performance
proportion for the entire state. For a given performance indicator,
the proportion of PMVs providing adequate services for Jigawa
was estimated by weighting results from each SD by the total
number of HFs in each SD and calculating the mean for the state
(Jigawa). Confidence intervals were calculated using a finite
population correction [35]. Analyses used ExcelH and the
Statistical Package for Social SciencesH (SSPS Version 15).
Results
Data collectors interviewed 21 PMVs (7 in each SD). PMVs in
the sample had store fronts rather than kiosks or a mobile outlet
type of service delivery (100%); vendors tended to have secondary
school education (38.1%) or above (57.1%, 5% no response), had a
median of 5 years experience (interquartile range (IQR)–2.0–16.0),
and attended to a median of 10 malaria cases (IQR 7.0–18.8) the
day preceding the survey. Only one PMV was female (4.8%).
Inputs and Processes: Stocks of Antimalarial Drugs and
ITNs, and PMV Training
All three SDs failed to have an adequate proportion of PMVs
stocking first-line antimalarials (Table 2). PMVs tended to stock
drugs no longer recommended for treatment of uncomplicated
malaria, especially Artesunate monotherapy, SP and CQ (Table 3).
Similarly, 42.35% of PMVs stocked ACT brands that were not
Ministry of Health (MOH) approved (Table 4). No SD displayed
adequate PMV training on relevant malaria-related topics
(Table 2).
Output Indicators: PMV Knowledge and Reported
Purchasing Behavior
No SD reached the 80% performance standard for any of four
output indicators. PMV knowledge of the Government recom-
mendations on the treatment of uncomplicated malaria was poor
in all SDs with less than 10% of PMVs being sufficiently familiar
with the new treatment policy (Table 2). SDs also exhibited
inadequate PMV knowledge on the correct dosage of ACTs for a
two-year old child and on recognizable danger signs necessitating
hospital referral (Table 2).
Table 1. Jigawa State with three Senatorial Districts by total number of Health Facilities (HFs), PMVs, sample sizes, and alpha and
beta errors for an LQAS decision rule of ‘‘d’’ = 5.
Senatorial District
Total Number of HFs
(N) Sample size of HFs (n)
Corresponding sample
size for PMVs (n) Alpha Error Beta Error
Central 10 7 7 ,0.001 0.083
North East 9 7 7 0.042 0.051
North West 9 7 7 0.042 0.051
doi:10.1371/journal.pone.0044775.t001
Medicine Vendors as Agents in Malaria Control
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Figure 1. Operating Characteristic Curve for health facility assessments in Jigawa, Nigeria. Operating Characteristic Curve for health
facility assessments with sample size n= 7 and a decision rule of d = 5 for the upper cut-off PU = 80% and the lower cut-off PL = 50% for Senatorial
Districts with a total of N= 9 and 10 health facilities. The area in between the upper and lower cut-off is the ‘‘grey area’’. Changing d would shift the
curve to the left or right; increasing the sample size would result in a sharper gradient of the curve and a smaller grey area. However, no matter how
large the sample size there will always be a grey area and a certain level of misclassification error. We selected n and d to reduce the two forms of
misclassification errors; it was ensured that the alpha error or the probability of mistakenly failing to accept an SD with acceptable performance
($80%) did not exceed a value of 0.10, and that similarly the beta error or the probability of mistakenly accepting an SD with unacceptable
performance (#50%) did not exceed 0.10.
doi:10.1371/journal.pone.0044775.g001
Table 2. Input, Process and Output indicators and LQAS judgment for three Senatorial Districts (C-Central, NE-North East, NW-
North West) in Jigawa, Nigeria, 2009.
Level Indicator
LQAS Judgment for each district
(n = 7 and d=5)*
Weighted State
aggregate CI{
C NE NW
Input PMVs with at least one first line antimalarial (ACTs) in stock{ 3= Low 4= Low 4= Low 52.04% 610.79%
PMVs with at least one ITN/LLIN in stock{ 0= Low 0= Low 1= Low 4.59% 64.24%
Process PMVs received malaria-related training in the past 3 years1 1= Low 1= Low 1= Low 14.29% 67.63%
Output PMVs have knowledge of Government recommendations on
treatment of uncomplicated malaria{{
1= Low 0= Low 1= Low 9.69% 66.34%
PMVs correctly described dosage of ACTs (AL and AA) for a
2 year old child11
1= Low 3= Low 1= Low 23.47% 68.73%
PMVs recognized at least 3 danger signs in children needing
referral
1 = Low 1= Low 1= Low 14.29% 67.63%
PMVs who sold a first line antimalarial (ACTs) as a treatment
for fever/malaria**
2 = Low 2= Low 2= Low 28.57% 69.85%
*Number of adequately performing PMVs in the sample of n = 7 PMVs per SD and classification of SD as high or low performance based on the decision rule (d = 5).
{95% confidence intervals for state estimates of coverage with finite population correction.
{as observed on the day of the survey.
1PMV reported having had malaria-related training on at least three of the following components: treatment with ACTs, promotion of ITNs, referral for danger signs,
disuse of chloroquine and SP for treatment.
{{PMV mentioned at least four of the following components of government recommendations: Treatment with ACTs, disuse of chloroquine and SP for treatment, disuse
of oral artemisinin-based monotherapy for treatment, antimalarials to be given in single treatment packs, SP to be provided at least twice during pregnancy, treatment
sought for febrile cases within 24 hrs of onset of symptoms.
11Interviewers brought the most common available brand of both types of recommended ACTs, showed them to the PMV and then asked them the dosage for a 2-year-
old child for each drug. PMVs were not restricted from looking up dosage information if they wanted to do so.
"Recognizable danger signs to be named included convulsions, coma, severe vomiting, inability to drink or breastfeed, severe sickness/inability to sit or stand, difficulty
in breathing/fast breathing, persistent fever, and lack of improvement or worsening of symptoms after two days.
**PMV reported that client looking for treatment of fever/malaria purchased a first line antimalarial (recommended ACTs) rather than a non-recommended antimalarial.
AL =Arthemether-lumefantrine, AA=Artesunate-amodiaquine, ITN = Insecticide Treated Nets, LLIN = Long Lasting Insecticide treated Nets.
doi:10.1371/journal.pone.0044775.t002
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Finally, no SD had an adequate proportion of PMVs selling
appropriate antimalarials. Less than 30% of PMVs reported
having sold first-line antimalarials to malaria patients the previous
day (Table 2), and about half of PMVs sold no longer
recommended Artesunate monotherapy, CQ and SP (Table 3).
Discussion
This study shows that PMVs, who are a relevant source of
malaria treatment, performed poorly for all input, process and
output indicators. On the input level ACT availability in PMV
stores was low (52.04%), despite being higher than availabilities
reported in the grey literature in 2007 for other states (Oyo,
Kaduna and Enugu), where on average 8.5% of PMV shops
stocked ACTs [36]. A 2008 report found that 19% of drug stores
in Nigeria stocked ACT [37]. In contrast, during 2009 researchers
in Enugu documented that ACT could be found in 89.6% of
medicine retailers; results were not reported for PMVs alone and
are difficult to compare with our findings [28]. While the
availability of ACT in our study was poor, the availability of
non-recommended antimalarials (SP (52.6%), CQ (46.4%),
Artenusate monotherapy (57.1%)) was high. This is a pattern also
found in the above mentioned studies [36,37].
These findings are disturbing given that changes to Nigeria’s
malaria treatment policy adopted ACT as the first-line treatment
in 2005. At that time the National Administration of Food and
Drugs Agency (NAFDAC) in collaboration with NMCP also
declassified ACT from prescription only to an over-the-counter
medicine, thus allowing its dissemination by PMVs. Simulta-
neously they discontinued the registration of artemisinin mono-
therapy, to prevent development of drug resistance [17,38]. The
drug availability described above and results from HFAs [28],
suggest that these policies were not sufficiently implemented within
the first four years following their introduction.
One reason PMVs to not adhere to the new guidelines in
Nigeria might be due to the fact that the approved drug list given
to PMVs upon registration and licensing had been last revised in
2003, and did not yet reflect the policy changes. The list did not
indicate ACT, but rather CQ and SP as approved drugs for
malaria treatment, which might have confused PMVs [39].
Besides this deficiency, and a lack of training and provider
knowledge, limited consumer demand and the higher cost of
ACTs might be additional reasons for low compliance with the
new guidelines.
On the process level our PMV-LQAS survey found that only
14.3% of PMVs had been trained on malaria-related topics in the
past three years, although PMV training had been included in the
2005–2010 strategic plan [17]. Previous studies report results that
are less specific and thus difficult to compare, but suggest that the
amount of training varies in different regions [28,36]. A likely
explanation for the absence of PMV training is that the
Pharmacists Council of Nigeria (PCN), the regulating body for
PMVs, was non-existent in Jigawa until a few months before this
research. There has been little delineation of roles among the
PCN, local government and other regulatory agencies about
which of them should be responsible for monitoring PMVs.
Problems of duplication of roles and bottlenecks surrounding the
registration, licensing and monitoring of PMVs in the state could
also partly explain other results reported above.
Given our findings about inputs and processes, poor perfor-
mance on the output level was not surprising. In all three SDs the
majority of PMVs was ignorant of the government’s recommen-
dations on malaria treatment. In a previous report, PMVs
knowledge on the change of policy related to first-line antimalar-
ials was low, but interestingly, it differed across the states and
regions, and might be explained by the fact that in one region,
drug companies rather than the government were the main source
of information on drug regulation [4]. Another report documented
that knowledge of the new first-line regimens was lowest in drug
stores, but only slightly better in formal private outlets and better,
but still insufficient, in public health facilities [37].
Poor PMV knowledge about the disuse of oral artemisinin
monotherapy for malaria treatment has been of particular
concern. In Nigeria and elsewhere many PMVs still mistakenly
consider artemisinin monotherapy as an ACT [21,40]. Both the
use of artemisinin monotherapy and incomplete dosages of ACT
harbor a significant risk for emergence of drug resistance [19,20],
and might have contributed to the declining ACT efficacy recently
observed on the Cambodia-Thailand border [41]. It is alarming
that only 23.5% of PMVs knew the correct ACT dosage for a 2-
year old child. In addition to the risk of drug resistance, incorrect
dosages might lead to increased adverse events or treatment failure
with grave health-related and economic consequences. Similarly,
PMVs’ failure to recognize danger signs in children (as observed in
this study and a previous one [37]) and to refer possible cases of
severe malaria to higher-level care, can lead to increased child
morbidity and mortality.
Given the observed drug availability pattern and the lack of
PMV knowledge discussed above, our findings were not
Table 4. Available ACT brands observed on the survey day in PMV stores in Jigawa, Nigeria*.
Policy Brand (generic) No. of PMV in SD
{
Weighted State
Aggregate CI{
C NE NW
MOH approved Coartem (AL) 0 3 2 22.96% 68.12
Arsuamoon (AA) 1 1 1 14.29% 67.63
Malact (AA) 0 2 0 9.18% 65.48
Nexanate (AA) 0 0 0 0% 60
Not MOH approved Others 2 4 3 42.35% 610.44
*Multiple responses were allowed; no LQAS judgments made, because list includes adequate and inadequate behavior, i.e. stocking and selling of brands that are MOH
approved and non-approved for treatment of uncomplicated malaria in Nigeria.
{Number of PMVs in the sample of 7 PMVs per Sub-District (SD) who had brands in stock as observed on survey day.
{95% confidence intervals for state estimates of coverage with finite population correction.
MOH=Ministry of Health, AL =Arthemether-lumefantrine, AA=Artesunate-amodiaquine.
doi:10.1371/journal.pone.0044775.t004
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unexpected that PMVs favored non-recommended antimalarials.
These results were consistent with a previous report [37]. While
recent data on PMVs’ ACT dispensing behavior in Africa are
scarce, pre-ACT era studies revealed incorrect dosing and
irrational prescribing practices, including the dispensing of
counterfeit and poor quality drugs; some of these studies suggested
PMVs were influenced by advertising and profit motives
[1,5,12,42,43]. However, PMVs are influenced by both supply
side and demand side factors [11,13,44], and by the way drug
distribution and health care is organized within the state [44].
These factors need further study to better understand how they
influence PMV performance in the ACT era. Future surveys could
include demand side indicators, and assess the knowledge,
expectations, and service satisfaction of clients through observa-
tions of provider-client interactions or client exit interviews. It
should also learn whether a client’s choice of antimalarials relies
on PMV advice, or prescriptions by other providers, or their own
decisions. Studies from the pre-ACT era revealed that most PMVs
simply sold drugs that a customer requested, without giving advice
and without requesting a prescription [9,11]. A limitation of our
study is that we did not record the price of drugs and explore its
effect on provider and consumer behavior. Previous studies found
that providers prescribe and dispense types and dosages of drugs
not according to need, but according to a patient’s ability to pay,
resulting in over-prescription or under-dosage of drugs [5,18]. The
assessment of the price of antimalarials at PMV stores will be all
the more important in the future, with the implementation of
structural interventions to improve ACT supply. Nigeria is one of
the pilot countries of the Affordable Medicines Facility-malaria
(AMFm) project launched in 2010 that aims to increase ACT
availability by subsidizing ACTs purchased by eligible 1st-line
buyers [45]. The AMFm Task Force has planned periodic ACT
price and availability monitoring surveys at different outlets, which
will hopefully also examine whether price reductions on top of the
supply chain will be passed on to consumers at PMV stores.
Further studies should also examine the quality of drugs, either
indirectly by checking storage conditions, packaging, expiry dates
and the presence of a NAFDAC registration number [36], or
directly by chemical testing [42]. Finally, future studies should
document the availability and use of rapid diagnostic tests (RDT)
by PMVs, should RDT be introduced for sale and use by PMVs.
This option is under consideration by the MOH provided PMVs
receive appropriate training, followed by regular supervision and
quality assurance [38,46].
LQAS has several strengths giving it an advantage over other
common survey methods, such as cluster surveys, which have been
used widely to assess immunization coverage and other health
outcomes [47]. LQAS has been shown to be cost-effective for
different public health applications, and especially if carried out in a
decentralized way by trained health workers as part of routine
monitoring, it requires less time and resources than cluster surveys
[48,49,50]. LQAS data collection does not seriously compete for
health workers’ time for providing health services, because only very
small sample sizes are required to make performance judgments
about a catchment area. Besides, sampling procedures and analysis,
originally developed for use by assembly line supervisors of
yesteryear, are simple and do not require substantial training [48].
As mentioned above, LQAS not only provides results on whether a
lot or SD showed acceptable or unacceptable performance, but also
allows combining results to provide the same state- and national-level
information that other multistage surveys provide. Another interest-
ing quality of LQAS is that it could be integrated into multistage
cluster sampling surveys, as recently demonstrated for the malaria
indicator survey [51]. These survey types are not intended, as is
LQAS, to reveal variation among different local sub-areas [48,52].
In our study we did not find much variation between different
supervision areas, because all SDs performed poorly for all key
indicators. However, LQAS has shown from previous studies that it
is an excellent tool to monitor progress of interventions and identify
problematic sub-areas in need of special action, which would not
have been identified by other survey types that report only on higher-
level overall coverage values [29,48,49]. With the effective use of our
data and the implementation of targeted interventions, PMV
performance will hopefully improve in the future, probably gradually
and especially on those aspects and in those areas where
interventions have been most successful. For example, if during
future monitoring it is found that PMVs in certain SDs perform
adequately for key indicators, while others show inadequate
performance, the latter might be able to learn from the experience
of successful SDs. By empowering program managers to make data-
driven decisions at decentralized levels, LQAS enables rapid
responses targeted to the local context. LQAS will also be useful to
compare pooled results of different geopolitical zones of the country,
given that the population, culture, customs, and also certain aspects
of the health care market differ between different states [4,9].
We also recommend that future PMV assessments be integrated
to complement HFAs, to monitor progress towards achievement of
international and national targets and to evaluate the effectiveness
of strategies. Having evaluators assess the PMV store nearest to the
previously examined HF is a practical way of integrating HF and
PMV assessments. This type of dual assessment is possible even if
our assumption that ACT demand could be highest at these PMV
stores might not be true. By the time our study was implemented,
no interventions targeting PMVs had taken place in Jigawa. Our
study was conducted as part of a baseline assessment among public
and private health care providers prior to the implementation of
interventions of the Malaria Booster Program. It also pre-dated
the roll-out of other projects, such as the AMFm.
In general, a number of strategies have been suggested that
target supply and demand side influences, and the prevailing
market environment [3,13,44,53,54,55]. A recent review [12]
summarized the limited evidence available concluding that
interventions had the potential to increase malaria-related
practices of PMVs in Africa, but that a country’s legal and market
environment had to be well analyzed and buy-in from all main
stakeholders had to be gained. A combination of different
approaches and strategies, which includes continued training
and supervision, could have great chance for success [12].
Conclusion
There is an urgent need to regularly monitor and improve the
availability and quality of malaria treatment and advice provided
by PMVs in Nigeria. The irrational use of antimalarials in the
ACT era revealed in this study bears a high risk of economic loss,
death and development of drug resistance. A combination of
strategies underpinned by descriptive and operational research
that further examine relevant factors and indicators is necessary
for an effective and sustainable collaboration with PMVs
[12,44,53]. LQAS has been shown to be a suitable method to
monitor malaria-related indicators among PMVs and should be
further applied across the country to effectively improve service
delivery.
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